4.7 Review

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

期刊

NATURE REVIEWS CANCER
卷 14, 期 7, 页码 455-467

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3760

关键词

-

类别

资金

  1. NCI NIH HHS [R01 CA176839, R01 CA131261] Funding Source: Medline
  2. NIGMS NIH HHS [T32 GM064337] Funding Source: Medline

向作者/读者索取更多资源

The identification of mutationally activated BRAF in many cancers altered our conception of the part played by the RAF family of protein kinases in oncogenesis. In this Review, we describe the development of BRAF inhibitors and the results that have emerged from their analysis in both the laboratory and the clinic. We discuss the spectrum of RAF mutations in human cancer and the complex interplay between the tissue of origin and the response to RAF inhibition. Finally, we enumerate mechanisms of resistance to BRAF inhibition that have been characterized and postulate how strategies of RAF pathway inhibition may be extended in scope to benefit not only the thousands of patients who are diagnosed annually with BRAF-mutated metastatic melanoma but also the larger patient population with malignancies harbouring mutationally activated RAF genes that are ineffectively treated with the current generation of BRAF kinase inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据